Use of vasopeptidase inhibitors in the treatment of metabolic disorders, nephropathy and AGE-associated disorders

摘要

The invention describes the use of vasopeptidase inhibitors of the formula DOLLAR F1 for the treatment and / or prophylaxis of nephropathy in patients suffering from diabetes or not suffering from diabetes, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, microalbuminuria or terminal renal insufficiency or insulin resistance, or of metabolic diseases associated with the advanced glycosylation endproducts, e.g. As diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and / or diabetic cardiomyopathy or atherosclerosis or endothelial dysfunction.